The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
 
Naoko Matsuda
No Relationships to Disclose
 
Ricardo H. Alvarez
No Relationships to Disclose
 
Savitri Krishnamurthy
No Relationships to Disclose
 
Jie S. Willey
No Relationships to Disclose
 
Xiaoping Wang
No Relationships to Disclose
 
Bora Lim
No Relationships to Disclose
 
Charla A. Parker
No Relationships to Disclose
 
Angela Marx
No Relationships to Disclose
 
Gildy Babiera
No Relationships to Disclose
 
Daniel J. Booser
No Relationships to Disclose
 
James L. Murray
No Relationships to Disclose
 
Banu Arun
Research Funding - Avon Foundation; NCI; NCI, Susan G. Komen, Avon; Susan G. Komen for the Cure
 
Abenaa M. Brewster
No Relationships to Disclose
 
James M. Reuben
No Relationships to Disclose
 
Wendy A. Woodward
No Relationships to Disclose
 
Anthony Lucci
No Relationships to Disclose
 
Sarah Marie Gainer
No Relationships to Disclose
 
Debu Tripathy
Consulting or Advisory Role - Eisai; OncoPlex Diagnostics
Research Funding - Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Eisai
 
Vicente Valero
No Relationships to Disclose
 
Naoto T. Ueno
Research Funding - Amgen; Celgene